Latest News About Hepcidin Antimicrobial Peptide

I can’t reliably pull the very latest (e.g., “this week/month”) updates right now, but here are relevant recent-to-midtime scientific updates on hepcidin’s antimicrobial activity and related therapeutic directions.

Recent research themes (what’s been moving)

• Hepcidin-derived peptides as antimicrobials (especially in aquatic models): Reviews and experimental work have focused on hepcidin-derived peptides (often called “hamp” in fish models) and whether specific variants reduce bacterial burden or mortality, sometimes showing that different peptide forms behave differently in vivo.[2][3]
• Mechanistic/optimization work around activity at physiological conditions: Literature emphasizes that antibacterial activity can depend strongly on conditions such as pH and on peptide form (mature peptide vs. fragments/derivatives), which matters for therapeutic translation.[1]

Example of a concrete in vivo result (fish infection model)

A Frontiers review describing experimental models reports that pre-administration of one hepcidin-derived peptide (notably “hamp2”) reduced mortality in an infection model far more than another form (“hamp1”) in that study.[3][2]

If you want, I can narrow it further

Tell me which of these you mean by “latest news,” and I’ll focus the search accordingly: 1) Human clinical trials involving hepcidin/derivatives
2) Antimicrobial peptides/host defense papers (mechanisms, in vitro)
3) Aquaculture use of hepcidin-like peptides (common in the newer AMP literature)

Also, do you want only 2026 items, or “latest 3–12 months”?